MANCHESTER, England, March 27, 2017 /PRNewswire/ --
Significant Step in Commercialisation of HCV Assay for Decentralised Use in Resource Limited Settings
genedrive plc, the near patient molecular diagnostics company, today announces submission of its GenedriveŽ HCV ID Kit for CE IVD certification under the EU Medical
The application for CE Marking is supported by excellent performance data in recent clinical validation studies. These studies, performed at Institut Pasteur, Paris, and Queen's Medical Centre, Nottingham, show that the GenedriveŽ HCV ID Kit sensitivity, specificity, and limit of detection meet the Target Product Profile specifications for decentralised use in resource limited setting as outlined by the Foundation for Innovation in Diagnostics (FIND).
The qualitative molecular HCV assay allows for decentralised testing of Hepatitis C (HCV), providing results within 90 minutes direct from a small plasma sample (25ul). The GenedriveŽ HCV assay demonstrated a sensitivity of greater than 99% and specificity of 100% over the 955 sample cohort when comparing the assay to the Abbott Molecular RealTime HCV Viral Load test. The assay is performed on the GenedriveŽ platform, a portable molecular diagnostics system designed for use at the point of need.
Professor William Irving, Professor of Virology at Queens Medical Centre, Nottingham, and clinical virology expert in hepatitis diagnosis, management and pathogenesis, was the lead investigator at the UK site involved with the clinical performance assessment of the GenedriveŽ HCV assay.
Professor Irving said, "The diagnostic and treatment landscape for HCV has changed rapidly in recent years, and with the introduction of direct acting antivirals, there is a real opportunity to tackle the global burden of Hepatitis C. Accurate, decentralised diagnostics, like GenedriveŽ HCV, promise to be a big step forward in addressing the challenges associated with identifying and diagnosing those living with HCV infection and to give them access to this new and effective therapy."
David Budd, Chief Executive Officer of genedrive plc said, "Application for CE Marking for the GenedriveŽ HCV assay is a significant step in our development of a decentralised and qualitative molecular HCV test, which could be the first of its kind to market. As we go through this process, we look forward to updating the market with our commercial partnership arrangements and target geographies for initial product introductions."
Notes to Editors
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The GenedriveŽ platform and MTB/RIF test have been launched in India and a GenedriveŽ HCV test has been successfully assessed by the Institut Pasteur, Paris.
Further details can be found at: www.genedriveplc.com and www.genedrive.com
About Hepatitis C
Hepatitis C is an international public health challenge, comparable to other major communicable diseases, including HIV, tuberculosis and malaria. It is estimated that 150-200 million people, or approximately 3% of the world's population, are living with chronic hepatitis C, and more than 350,000 people die yearly from hepatitis C related diseases. In 2016, WHO published the first global health sector strategy on Hepatitis with a goal of eliminating viral hepatitis as a major public health threat by 2030. New oral, well-tolerated treatment regimens can achieve cure rates of over 90% however access to rapid, inexpensive and accurate diagnostics are a critical bottleneck that must be addressed to eradicate Hepatitis C.
For further details please contact: genedrive plc David Budd, CEO Matthew Fowler, CFO +44-(0)-161-989-0245 Peel Hunt LLP James Steel Oliver Jackson +44-(0)-207-418-8900 Consilium Strategic Communications Chris Gardner Matthew Neal Laura Thornton +44-(0)-203-709-5700 firstname.lastname@example.org
SOURCE genedrive plc
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All